United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - milrinone - solution for infusion - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

peckforton pharmaceuticals ltd - milrinone - solution for infusion - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

stragen uk ltd - milrinone - solution for infusion - 1mg/1ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

boston oncology arabia, saudi arabia - milrinone - solution for injection - 1 mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

macure pharma uk ltd - milrinone - solution for infusion - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - milrinone lactate - solution for injection - 1mg/1ml

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

stragen nordic a.s. - milrinone 1 mg/ml - concentrate for solution for infusion - milrinone

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

stragen nordic a.s. - milrinone 1 mg/ml - concentrate for solution for infusion - milrinone

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

takata pharmaceutical co., ltd. - milrinone - injection

Israel - English - Ministry of Health

sanofi israel ltd - milrinone - solution for injection - milrinone 1 mg/ml - milrinone - milrinone - for the treatment of refractory heart failure immediately (up to 72 hours) following cardiac surgery. for the short term ( up to 48 hours) intravenous therapy of severe refractory congestive heart failure.in pediatric population primacor is indicated for the short-term treatment (up to 35 hours) of severe congestive heart failure unresponsive to conventional maintenance therapy (glycosides, diuretics, vasodilators and/or angiotensin converting enzyme (ace) inhibitors), and for the short-term treatment (up to 35 hours) of pediatric patients with acute heart failure, including low output states following cardiac surgery.